Imagion Biosystems Limited IBXXF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2,176.83% | 2,153.09% | -95.38% | -95.51% | -98.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,176.83% | 2,153.09% | -95.38% | -95.51% | -98.48% |
| Cost of Revenue | 188.06% | 187.64% | 2,104.05% | 2,039.47% | 78.58% |
| Gross Profit | -101.17% | -100.87% | -251.18% | -246.54% | -143.74% |
| SG&A Expenses | 33.70% | 33.45% | 17.97% | 14.33% | -70.35% |
| Depreciation & Amortization | -50.00% | -50.00% | -44.00% | -46.15% | -98.89% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 113.58% | 113.21% | 183.60% | 174.90% | -55.25% |
| Operating Income | -67.71% | -67.47% | -1,458.95% | -1,417.58% | -21.35% |
| Income Before Tax | -32.15% | -31.95% | -393.75% | -378.56% | -5.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.15% | -31.95% | -393.75% | -378.56% | -5.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.15% | -31.95% | -393.75% | -378.56% | -5.78% |
| EBIT | -67.71% | -67.47% | -1,458.95% | -1,417.58% | -21.35% |
| EBITDA | -68.21% | -67.93% | -1,293.06% | -820.95% | -107.10% |
| EPS Basic | 46.15% | 46.15% | 19.35% | 21.88% | 83.12% |
| Normalized Basic EPS | 47.06% | 43.75% | 21.05% | 25.00% | 82.29% |
| EPS Diluted | 48.15% | 46.15% | 19.35% | 21.88% | 82.47% |
| Normalized Diluted EPS | 47.06% | 43.75% | 21.05% | 25.00% | 82.29% |
| Average Basic Shares Outstanding | 143.60% | 143.60% | 517.65% | 517.65% | 516.73% |
| Average Diluted Shares Outstanding | 143.60% | 143.60% | 517.65% | 517.65% | 516.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |